These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 23137712)

  • 21. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review.
    Ratjen F; Brockhaus F; Angyalosi G
    J Cyst Fibros; 2009 Dec; 8(6):361-9. PubMed ID: 19747887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pseudomonas aeruginosa infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches.
    Lund-Palau H; Turnbull AR; Bush A; Bardin E; Cameron L; Soren O; Wierre-Gore N; Alton EW; Bundy JG; Connett G; Faust SN; Filloux A; Freemont P; Jones A; Khoo V; Morales S; Murphy R; Pabary R; Simbo A; Schelenz S; Takats Z; Webb J; Williams HD; Davies JC
    Expert Rev Respir Med; 2016 Jun; 10(6):685-97. PubMed ID: 27175979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients.
    Ciofu O; Tolker-Nielsen T; Jensen PØ; Wang H; Høiby N
    Adv Drug Deliv Rev; 2015 May; 85():7-23. PubMed ID: 25477303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bacterial Culture Underestimates Lung Pathogen Detection and Infection Status in Cystic Fibrosis.
    Gavillet H; Hatfield L; Rivett D; Jones A; Maitra A; Horsley A; van der Gast C
    Microbiol Spectr; 2022 Oct; 10(5):e0041922. PubMed ID: 35972283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Off-label use of intravenous antimicrobials for inhalation in patients with cystic fibrosis.
    McKinzie CJ; Chen L; Ehlert K; Grisso AG; Linafelter A; Lubsch L; O'Brien CE; Pan AC; Wright BA; Elson EC
    Pediatr Pulmonol; 2019 Nov; 54 Suppl 3():S27-S45. PubMed ID: 31715085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Ratjen F
    Curr Opin Pulm Med; 2006 Nov; 12(6):428-32. PubMed ID: 17053493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eradication of early Pseudomonas infection in cystic fibrosis.
    Lee TW
    Chron Respir Dis; 2009; 6(2):99-107. PubMed ID: 19411571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of antibiotic susceptibility patterns in Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) with invasive Pseudomonas aeruginosa from non-CF patients.
    Rao P; McCaughan J; McCalmont M; Goldsmith CE; Hall V; Millar BC; McCann MA; Downey DG; Rendall JC; Elborn JS; Moore JE
    J Cyst Fibros; 2012 Jul; 11(4):349-52. PubMed ID: 22325689
    [No Abstract]   [Full Text] [Related]  

  • 29. Pathophysiology and management of pulmonary infections in cystic fibrosis.
    Gibson RL; Burns JL; Ramsey BW
    Am J Respir Crit Care Med; 2003 Oct; 168(8):918-51. PubMed ID: 14555458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimicrobial Strategies for Cystic Fibrosis.
    Møller R; Pressler T; Qvist T
    Semin Respir Crit Care Med; 2023 Apr; 44(2):297-306. PubMed ID: 36535665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pseudomonas aeruginosa hypoxic or anaerobic biofilm infections within cystic fibrosis airways.
    Hassett DJ; Sutton MD; Schurr MJ; Herr AB; Caldwell CC; Matu JO
    Trends Microbiol; 2009 Mar; 17(3):130-8. PubMed ID: 19231190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhaled antibiotics in Cystic Fibrosis (CF) and non-CF bronchiectasis.
    Tay GT; Reid DW; Bell SC
    Semin Respir Crit Care Med; 2015 Apr; 36(2):267-86. PubMed ID: 25826593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early Pseudomonas aeruginosa infection in individuals with cystic fibrosis: is susceptibility testing justified?
    Macdonald D; Cuthbertson L; Doherty C; Campana S; Ravenni N; Taccetti G; Govan JR
    J Antimicrob Chemother; 2010 Nov; 65(11):2373-5. PubMed ID: 20837573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eradication therapy for Pseudomonas aeruginosa colonization episodes in cystic fibrosis patients not chronically colonized by P. aeruginosa.
    Schelstraete P; Haerynck F; Van daele S; Deseyne S; De Baets F
    J Cyst Fibros; 2013 Jan; 12(1):1-8. PubMed ID: 22939202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.
    Tiddens HA; De Boeck K; Clancy JP; Fayon M; H G M A; Bresnik M; Derchak A; Lewis SA; Oermann CM;
    J Cyst Fibros; 2015 Jan; 14(1):111-9. PubMed ID: 25091537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pseudomonas aeruginosa pneumonia.
    Garau J; Gomez L
    Curr Opin Infect Dis; 2003 Apr; 16(2):135-43. PubMed ID: 12734446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gerimax ginseng regulates both humoral and cellular immunity during chronic Pseudomonas aeruginosa lung infection.
    Song Z; Wu H; Mathee K; Høiby N; Kharazmi A
    J Altern Complement Med; 2002 Aug; 8(4):459-66. PubMed ID: 12230906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibiotic treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.
    Møller NE; Høiby N
    Scand J Infect Dis Suppl; 1981; 29():87-91. PubMed ID: 6458884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis.
    Treggiari MM; Rosenfeld M; Retsch-Bogart G; Gibson R; Ramsey B
    Pediatr Pulmonol; 2007 Sep; 42(9):751-6. PubMed ID: 17647287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continuous infusion meropenem and ticarcillin-clavulanate in pediatric cystic fibrosis patients.
    Zobell JT; Ferdinand C; Young DC
    Pediatr Pulmonol; 2014 Mar; 49(3):302-6. PubMed ID: 23775821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.